Karachi, Highnoon Laboratories Limited informed Pakistan Stock Exchange about the recommendations made by the board of directors in the meeting held at Lahore on April 29, 2019.
The agenda of the meeting was discussion of consolidated profit and loss account for quarter ended March 31, 2019 which portrayed a profit of Rs. 229,088,920 with earnings per share 8.01 basic and diluted respectively.
Further, nil payment of cash dividend, bonus shares and right shares was agreed.
Highnoon Laboratories Limited was incorporated in March 1984 as a Private Limited Company in the historical and cultural city of Lahore, Pakistan. It became Public Limited Company in 1995 and the shares of the Company are listed on all the stock exchanges of Pakistan.
Right from its inception, alliance with some of the best-known research houses of the global pharmaceutical industry were forged by Highnoon. These alliances coupled with aggressive yet ethical marketing activities enabled Highnoon to become the first pharmaceutical Company of Pakistan origin to be in the top twenty league of Pakistan pharmaceutical industry.
Equally responsible for Highnoon’s success is the unshakeable consumer confidence that the Company has been able to build on the quality of its products manufactured in its ISO 9001:2008 approved facility.
Highnoon is continuously re-aligning its portfolio to ensure that it is able to harness opportunities. At the same time, the Company is modernizing its plant, by investing in new equipment and technology to upgrade its manufacturing facilities to comply with ‘Current Good Manufacturing Practices (cGMP)’.
Highnoon’s therapeutic focus in Cardiology, Gastroenterology, Respiratory and Diabetics has led to the development of franchises, which are now the most admired in the healthcare industry. Highnoon has since then, marched ahead introducing state of the art products and setting new trends.
The symbol “HINOON” is being used by the stock exchange for the shares of Highnoon Laboratories Limited.